Octreotide
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Octreotide: Vulvar inverted follicular keratosis
One-Sentence Summary
Octreotide is a somatostatin analog originally used to treat acromegaly, hyperpituitarism and carcinoid syndrome. The TxGNN model predicts it may be effective for vulvar inverted follicular keratosis, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on computational prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Vulvar inverted follicular keratosis |
| TxGNN Prediction Score | 0.9958 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, octreotide is a somatostatin analog that acts mainly on somatostatin receptors SSTR2 and SSTR5. Its efficacy in hormone-secreting conditions such as acromegaly and carcinoid syndrome is established.
For vulvar inverted follicular keratosis, a benign epithelial skin lesion, no plausible mechanistic link is supported by the available data. The high TxGNN score is a computational output only. It is likely driven by similarity to related entries, such as seborrheic keratosis, which also appears among the top predictions. This prediction should be treated as a hypothesis, not as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Octreotide is marketed in India as injectable products. There are 20 valid single-ingredient registrations and none are cancelled. The approved indication text is not available for these registrations. The five main authorizations are listed below.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 207477 | Sandostatin 0.05mg Injection | Vial of 1, injection | Novartis India Ltd |
| 201402 | Sandostatin LAR 20mg Injection | Vial of 1 ml, injection | Novartis India Ltd |
| 163875 | Octride Depot 10mg Injection | Vial of 1, injection | Sun Pharmaceutical Industries Ltd |
| 162773 | Octride 0.05mg Injection | Vial of 1 ml, injection | Sun Pharmaceutical Industries Ltd |
| 167046 | Okeron 0.05mg Injection | Vial of 1 ml, injection | Wockhardt Ltd |
Safety Considerations
- Disease-level cautions (from the knowledge graph, not label text): The knowledge graph links octreotide to contraindications or cautions in several conditions, including:
- Metabolic and endocrine: hyperglycemia, hypoglycemia, diabetes mellitus, diabetic ketoacidosis, hypothyroidism (including congenital hypothyroidism and myxedema)
- Hepatobiliary: liver disease, cirrhosis, gallbladder disease, cholelithiasis (including cholecystolithiasis and choledocholithiasis)
- Gastrointestinal: ileus, intestinal obstruction
- Cardiac: sudden cardiac arrest, heart conduction disease
- Renal and nutritional: kidney failure, uremia, vitamin B12 deficiency
- Drug Interactions: 272 interactions were recorded. The 20 listed are all of Moderate level and mostly involve glucose-lowering agents, including:
- Insulins (aspart, degludec, detemir, glargine, glulisine and human insulins)
- Metformin, acarbose and chlorpropamide
- Glimepiride
- DPP-4 inhibitors (alogliptin, linagliptin)
- GLP-1 agonists (albiglutide, dulaglutide, semaglutide)
- SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin)
Glucose monitoring is advisable when octreotide is combined with these agents.
Package insert warnings and contraindications were not available. Please refer to the package insert for the full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or literature (evidence level L5), and no plausible mechanistic link between somatostatin receptor agonism and a benign keratinocyte lesion. The other top-ranked predictions (such as seborrheic keratosis and several nephrotic syndromes) are also prediction-only.
To proceed, the following is needed:
- Package insert warnings and contraindications for the marketed Indian products. This is a blocking gap for safety screening.
- Mechanism of action data for octreotide, to assess any biological link to the predicted condition.
- Preclinical or mechanistic evidence showing somatostatin receptor involvement in the target skin lesion.
- Route compatibility assessment. Octreotide is only available as injections in India, which may not suit a benign skin lesion.
- A review of the other ranked predictions for any with stronger biological rationale.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.